Latest Articlesddd
Cassava Sciences Inc Opened Down Today Cassava Sciences, Inc. (SAVA) - a clinical-stage biotech firm focused on …
Cassava Sciences 2021 Focus and Momentum Cassava Sciences (SAVA) President & CEO, Remi Barbier, informed that …
The Children’s Hospital of Philadelphia: Improving Gene Therapy Vectors Improving gene therapy vectors seems to have …
Roche Group and Spark Therapeutics Gene Therapy Showing Promising Results Looking for gene therapy treatments for …
Cassava Sciences Announced Simufilam Results for Alzheimer's Cassava Sciences (SAVA) announced impressive results of an interim …
Amgen KRAS Inhibitor, Sotorasib Amgen (AMGN) has taken on one of the toughest challenges in the last …
Moderna COVID-19 Vaccination News A vaccination with the Moderna (MRNA) COVID-19 produced neutralizing titers against all …
CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL CASI Pharmaceuticals (CASI) partner BioInvent …
Aurinia Pharmaceuticals LUPKYNIS Approved for LN in Adults Aurinia Pharmaceuticals (AUPH) has been granted a U.S. …
Merck Discontinues Development of COVID-19 Vaccine Candidates Merck (MRK) known as MSD outside the United States and …
ViiV Healthcare Announced FDA Approval for Cabenuva for Adults with HIV-1 From London we learned that …
Exelixis: FDA Approval for Cabometyx in Combination with Opdivo Exelixis (EXEL) announced that the United States FDA …
The Compugen Story For those who are still asking about the value of Compugen’s (CGEN) discoveries …
Sutro Biopharma Therapeutic Discovery and Technology Sutro Biopharma (STRO) uses precise protein engineering and rational design …
Reata Pharmaceuticals The Positive News Prohost Biotech's interest in Reata Pharmaceuticals (RETA) started when we recognized …
bluebird bio Decision to Separate its Businesses bluebird bio (BLUE) will retain focus on its severe genetic …
La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA La Jolla Pharmaceutical …
Exelixis Bright Future Exelixis Fourth Quarter and Full Year 2020 Financial Results Exelixis (EXEL) announced …
Intellia Therapeutics and CRISPR/Cas9 Technology Intellia Therapeutics (NTLA) is a genome editing company, focused on the …
Rhythm Pharmaceuticals Announces Successful Phase 3 Trial Results for Obesity In November 2020, when the U.S. …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
